GLP-1 Drug Pricing Guide: Best Prices as of May 2026

The May 2026 GLP-1 pricing picture looks much like April on the surface. Underneath, three things have changed.

First, the higher-dose tier is now established. Wegovy HD (semaglutide 7.2 mg) won FDA approval in March 2026 and launched April 7. It ships at $399/month self-pay. Many commercially insured patients pay as low as $25/month through the savings offer. That price sits between standard Wegovy 2.4 mg and the next generation of gut-hormone drugs. Lilly's Foundayo (orforglipron) hit its fourth commercial week with 7,335 prescriptions, per Citi's May 8 note on IQVIA data. Telehealth platforms account for roughly 35% of launch volume, and the IQVIA retail tracker misses that share.

Second, the compounded-GLP-1 channel is closing. On April 30, the FDA proposed striking semaglutide, tirzepatide, and liraglutide from the 503B bulks list. 503B facilities compound drugs in large batches; 503A pharmacies fill patient-specific prescriptions. The 60-day comment window closes June 29. Once the rule is final, large-scale 503B compounding effectively ends. The 503A path stays open until the July 23-24 meeting of PCAC, the FDA's Pharmacy Compounding Advisory Committee. The direction is clear. Most patients now paying $159-$349/month for compounded versions will need to move to branded supply.

Third, the Medicare GLP-1 Bridge launches July 1. Eligible Medicare Part D (prescription drug plan) members will pay $50/month for Wegovy, Zepbound, and possibly Foundayo through December 31, 2027. State Medicaid programs began joining May 1 and can opt in through January 1, 2027. This is the first government-payer GLP-1 program with a set price, though eligibility is limited.

The bottom-line price points for May 2026: commercially insured patients still pay as low as $25/mo with a savings card. Uninsured self-pay starts at $149/mo (Foundayo LillyDirect starter, Wegovy pill 1.5 mg) and runs to $499/mo (Wegovy injectable at NovoCare). Medicare patients pay $50/mo through TrumpRx and, from July 1, the GLP-1 Bridge. WAC list prices (Wholesale Acquisition Cost, the manufacturer's sticker price) have barely moved and have little to do with what anyone pays.

For the full April baseline, see GLP-1 Pricing: April 2026. For the Medicare program in detail, see Medicare GLP-1 Bridge Pricing 2026. For the Canada generic semaglutide story, see Generic Semaglutide Canada Pricing.